Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level

Detailed Description
-----------------
Progestogen-only' contraceptives are presented as injections, implants, oral formulations, hormone-releasing intrauterine methods and emergency contraceptives. These substances could be used by females who are breastfeeding or have other contraindications to estrogen treatment, including those who are immediately postpartum, have thalassemia, sickle-cell disease, gallbladder disease, or currently experiencing thrombo-embolic disorders, valvular heart disease, ischemic heart disease. Intrauterine, injectable methods and contraceptive implants named as long-acting reversible contraceptives (LARC) are the more efficient reversible contraceptive approaches are highly effective, longer-acting contraceptive methods levels.

Official Title
-----------------
Effects of Different Progesterone Containing Contraceptive Methods on Safety and Endogenous Progesterone Level

Conditions
-----------------
Progesterone, Contraceptive Methods

Intervention / Treatment
-----------------
* Other: Depo-Provera
* Other: Implanon
* Other: Norgestrel
* Other: Mirena


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 80 healthy fertile females 20-35 years With normal menstrual history Had at least one offspring after spontaneous pregnancy Exclusion Criteria: Any disease affects uterus (uterine tumors fibroids, endometriosis, prolapse, or tuberculosis). Ovarian tumors submucous myoma irregular menstrual cycle past or family history of breast disease Diabetic patients, medication affecting reproductive or metabolic functions. endometrial thickness <7 mm on the secretory transformation day history of spontaneous abortions history of embryo transfer failure on over three occasions Patients had cortisol medications patients who received radiological treatment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Depo-Provera group<br>This group will receive150 mg of injectable progesterone every 90 days or 3 months | Other: Depo-Provera<br>* Injectable progesterone<br>|
| Implanon group<br>This group will receive 68 mg of etonogestrel implant formerly known as Implanon. | Other: Implanon<br>* Etonogestrel implant<br>|
| Norgestrel group<br>This group will receive 0.075 mg of norgestrel (Ovrette®) once daily. | Other: Norgestrel<br>* Pill containing progesterone<br>|
| Mirena group<br>This group will receive IUD (Mirena) containing 52 mg of levonorgestrel. | Other: Mirena<br>* Levonorgestrel-releasing intra-uterine drug (IUD)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level | The effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level will be recorded | Six mounths |